New Haystack MRD test shows 100% specificity and high sensitivity in detecting cancer recurrence.

A study published in The Journal of Molecular Diagnostics validates the Haystack MRD test's high accuracy in detecting residual and recurrent cancer, especially colorectal cancer, with 100% specificity and up to 100% sensitivity at 3 years. The test outperforms traditional biomarkers like CEA and can detect extremely low levels of circulating tumor DNA across 23 solid tumor types. This advancement supports more personalized cancer treatment decisions and earlier detection of recurrence, potentially improving patient outcomes. The test is commercially available and has received FDA Breakthrough Device Designation for stage II colorectal cancer.

Quest Diagnostics Inc (DGX) holds a market cap of $25.72 billion and offers a dividend yield of 1.48% as of Oct 01, 2026 19:44 WIB. The stock price is USD 233.96, showing a modest 0.38% increase on the day. This stable performance coincides with the news of Haystack MRD's strong clinical validation, highlighting ongoing innovation in cancer diagnostics within the health sector.